1. Introduction {#sec1}
===============

Higher acetylenic alcohols and their derivatives are encountered in many plants, algae, marine invertebrates, and higher fungus species,^[@ref1]−[@ref8]^ and more than 1000 acetylenic compounds have been isolated and identified to date. For many years, increasing interest has been shown in these organic compounds, largely owing to the important biological activities they exhibit, in particular, antitumor, antimicrobial, antiparasitic, antibacterial, antifungal, and other types of activities.^[@ref4]−[@ref16]^

Among the diverse alkynol derivatives known to date, derivatives of carbinols containing one or several triple bonds in the α-position to the hydroxy group are the most abundant.^[@ref1]−[@ref5]^

In addition, it has been shown by Japanese researchers that higher alkynols, lembehynes A--C, containing bis-methylene-separated Z-double bonds in the molecules, isolated in nanoconcentrations from Indonesian sea sponges *Haliclona* sp., show a high neuritogenic activity against mouse neuroblastoma Neuro 2A cells and rat pheochromocytoma PC12 cells.^[@ref17]−[@ref20]^

Therefore, these compounds can be considered as the base for the development of modern drugs for the treatment of neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, Huntington's chorea and so on).

Meanwhile, studies along this line were considerably held up by the exceptionally low content of lembehynes in sea sponges and the lack of efficient methods for their total synthesis. Therefore, we developed original stereoselective approaches both for the preparation of key monomers and for the total synthesis of lembehynes A and B^[@ref21]−[@ref24]^ using the Ti-catalyzed cross-cyclomagnesiation of oxygenated and aliphatic 1,2-dienes on treatment with Grignard reagents, which we discovered.^[@ref25]−[@ref27]^ In addition, it was shown for the first time by flow cytometry that lembehyne B can induce early apoptosis in various types of leukemia cells.^[@ref22]^

As a continuation of the studies dealing with stereoselective synthetic routes to lembehyne derivatives and the influence of their structure on the antitumor and neuritogenic activities, here, we report a stereoselective method for the synthesis of lembehyne B 1,3-diyne derivatives, close structural analogues of natural strongylodiols,^[@ref28]−[@ref30]^ pellynols,^[@ref31]^ and halicynones,^[@ref32]^ which exhibit a broad range of biological activities. In addition, we planned to pay particular attention to testing of the antitumor and neuritogenic activities of the compounds by means of modern flow cytometry and phase-contrast microscopy.

2. Results and Discussion {#sec2}
=========================

2.1. Chemistry {#sec2.1}
--------------

According to the previously developed scheme for the preparation of racemic lembehyne B,^[@ref21]^ we first prepared (13*Z*,17*Z*)-tetraconta-13,17-dienal (**4**) in a 79% yield by cross-cyclomagnesiation of 1,2-nonadediene (**1**) and 2-tetradeca-12,13-dien-1-yl-1,3-dioxolane (**2**) on treatment with EtMgBr in the presence of Mg metal and a catalytic amount of Cp~2~TiCl~2~ (10 mol %) (**1**/**2**/EtMgBr/Mg/\[Ti\] = 12:10:30:20:0.1, Et~2~O, 20--22 °C, 7 h) ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). This was followed by a successive reaction of aldehyde **4** with presynthesized 1-lithium-4-trimethylsilyl-1,3-butadiyne and removal of the trimethylsilyl group on treatment with trimethylbutylammonium fluoride (TBAF) in tetrahydrofuran (THF) to give the target 1,3-diyne rac-lembehyne B analogue **6** in ∼66% yield ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

![Synthesis of Racemic 1,3-Diyne's Lembehyne B Derivative **6**](ao9b03826_0008){#sch1}

Subsequently, we developed a synthetic route to 1,3-diyne derivatives of natural lembehyne B with the *R*-configuration of the hydroxy group by the direct addition of 1-bromoalkynes to lembehyne B^[@ref22]^ synthesized from aldehyde **4** according to [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}:

![Synthesis of 1,3-Diyne's Analogues **11** and **12a**--**d** on the Basis of Natural Lembehyne B (**10**)](ao9b03826_0003){#sch2}

First, racemic **8** and natural lembehyne B (**10**) were synthesized according to a previously developed scheme^[@ref21]−[@ref24]^ by the successive addition of lithium trimethylsilylacetylenide to aldehyde **4**, deprotection of the resulting alkyne **7**, oxidation of alcohol **8**, and stereoselective reduction of ketone **9** at the final step. The reactions of natural lembehyne B (**10**) with 1-bromo-2-trimethylsilylacetylene or 1-bromo-2-(ω-hydroxyalkyl)acetylenes in the presence of CuCl afforded the target 1,3-diyne lembehyne B derivatives **11** and **12a--d** in high yields.

In the second stage, we initiated a study of antitumor and neuritogenic activities of the synthesized 1,3-diynes in comparison with those of the initial lembehyne B.

2.2. Biology {#sec2.2}
------------

The cytotoxicity of lymbehynes B and their derivatives (altogether six compounds) was evaluated using a flow cytofluorimeter and a Guava ViaCount kit (Millipore). The following cell lines were studied: Jurkat (human T-lymphoblastic leukemia), K562 (human chronic myelogenous leukemia), U937 (human histiocytic lymphoma), HeLa (human cervical carcinoma), Hek293 (human embryonic kidney cells), and Neuro 2A cells. The neuroblastoma Neuro 2A cell line of mice (albino) is a convenient model to study the mechanisms of neuronal differentiation and the action of neurotrophic factors.

We tested two 1,3-diyne derivatives **6** and **11** based on the racemic and natural lembehyne B and four ω-hydroxy-1,3-diyne lembehyne B (**10**) derivatives (**12a--d**) with different distances between the hydroxy group and the 1,3-diyne moiety. Cytotoxicity assays of these compounds against Jurkat, K562, U937, and HeLa tumor cells and Hek293 embryonic cells showed that 1,3-diyne **6** based on racemic lembehyne B has a somewhat lower cytotoxic activity against these cell lines than its analogue **11** synthesized using natural lembehyne B. The highest cytotoxicity was found for compound **12c**, the cytotoxicity of which was higher for suspension cultures (Jurkat, K562, U937) than for adhesion cultures ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}).

###### Biological Activity of Lembehyne B 1,3-Diyne Derivatives

            cytotoxicity, IC~50~, μM (24 h)   neuritogenesis[a](#t1fn1){ref-type="table-fn"} 72 h, %                                                
  --------- --------------------------------- -------------------------------------------------------- -------------- -------------- -------------- --------
  **12a**   0.55 ± 0.041                      0.61 ± 0.046                                             0.52 ± 0.037   1.17 ± 0.079   0.97 ± 0.069   54 ± 4
  **12b**   0.47 ± 0.037                      0.54 ± 0.039                                             0.51 ± 0.034   1.01 ± 0.072   0.88 ± 0.071   61 ± 5
  **12c**   0.34 ± 0.031                      0.37 ± 0.021                                             0.32 ± 0.028   0.79 ± 0.051   0.63 ± 0.044   72 ± 6
  **12d**   0.52 ± 0.038                      0.59 ± 0.041                                             0.49 ± 0.039   1.35 ± 0.084   1.12 ± 0.075   68 ± 5
  **6**     0.69 ± 0.047                      0.74 ± 0.049                                             0.61 ± 0.042   1.42 ± 0.092   1.28 ± 0.081   44 ± 3
  **11**    0.65 ± 0.044                      0.71 ± 0.046                                             0.58 ± 0.039   1.38 ± 0.089   1.25 ± 0.079   49 ± 4
  **10**    0.53 ± 0.039                      0.69 ± 0.043                                             0.56 ± 0.040   2.84 ± 0.124   2.11 ± 0.097   56 ± 4
  **NGS**                                                                                                                                           44 ± 3

The maximum number of cells with neurites, whose length exceeds the body length of the neuron, observed in the concentration range 0.2 nM, incubation 72 h, in %.

The lembehyne B derivatives at a concentration of 0.60 μM/mL induced apoptosis of 87% of Jurkat tumor cells ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A), 15% being early apoptosis (Q7-4) and more than 71% being late apoptosis (Q7-2).

![Jurkat cells treated with different concentrations of compound **12c** (1) were double-stained with annexin V/PI and analyzed by flow cytometry. (A) 0.6 μM; (B) 0.4 μM; (C) 0.2 μM; (D) 0.1 μM; (E) control. Q7-1, necrotic cells; Q7-2, late apoptotic cells; Q7-3, living cells; Q7-4, early apoptotic cells.](ao9b03826_0004){#fig1}

Thus, lembehyne B derivatives show a dose-dependent influence on the cell population and induce early and late apoptosis; meanwhile, the initial lembehyne B has been previously shown to induce, most of all, early apoptosis.^[@ref22]^

[Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} shows the results of the study of the cell cycle phases for Jurkat cells carried out by flow cytometry within 24 h after the cells were treated with compound **12c** at various concentrations.

![Cell cycle analysis in Jurkat cells after incubation with compound **12c** at different concentrations for 24 h. (A) 0.6 μM; (B) 0.4 μM; (C) 0.2 μM; (D) 0.1 μM; (E) untreated cells.](ao9b03826_0007){#fig2}

The Jurkat, K562, U937, HeLa, and Hek293 cell cycle characteristics in the control samples showed a considerable predominance of cells in the G0--G1 phase and a balance between the synthesis (S phase) and apoptosis (sub-G0--G1) processes.

Within 24 h after exposure to compound **12c**, virtually in all tumor cell lines, most of all in the suspension Jurkat, K562, and U937 cells, apoptosis processes predominated (increased sub-G0--G1 stage), with retained or even somewhat enhanced ability of cells to DNA synthesis (S phase). This was accompanied by a decreasing fraction of cells in the G0--G1 phase, together with an increasing proliferation block and a decreasing proliferation index due to a decrease in the number of cells in the G2 + M phase ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A).

All of the foregoing may be indicative of the cytotoxic activity of compound **12c** against chronic myeloid, T-cell leukemia, and histiocytic lymphoma cells caused by the ability of these compounds to induce apoptosis.

A comparison of the data on the effects of natural lembehyne B and its 1,3-diyne analogue **12c** on the cell cycle showed some differences. Whereas lembehyne B mainly arrests the cell cycle in the G1 phase, apart from the accumulation of hypodiploid cells (G0), the 1,3-diyne analogues directly affect the S phase by stopping it and decreasing the G2 cell population, which also finally contributes to the hypodiploid cell population.

Like other derivatives that we studied, compound **12c** stimulated the growth of neurites in the Neuro 2A cell culture; however, unlike other compounds, **12c** showed a very high differentiating activity toward neuroblastoma cells, which was manifested even at low concentrations ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"} and [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). When the time of cell incubation with 1,3-diyne **12c** increased, the differentiation was enhanced and neurite branching and elongation took place ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). The advantage of the neurite branching and length for the cells incubated in the medium with compound **12c** can be clearly seen in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}. In other words, compound **12c** may prove to be not inferior in activity to neuro growth factor (NGF); however, for a better understanding of the cellular processes induced by lembehyne derivatives, further research into the molecular transformations involved in the lembehyne-induced neuritogenesis is required.

![Phase-contrast microscopy of neuritogenesis in the Neuro 2A cells induced by compound **12c** at the concentration of 0.2 nM. (A) Cell incubation with NGF for 72 h. Cell incubation with compound **12c** for (B) 24 h, (C) 48 h, (D) 72 h.](ao9b03826_0005){#fig3}

A completely different cell cycle situation is found by flow cytometry for the treatment of Neuro 2A cells with the lembehyne B derivative ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). The histograms of cell cycle phases in the Neuro 2A cells on exposure to compound **12c** show, first, somewhat enhanced capability of cells for DNA synthesis (increased S phase) and then, by the end of the third day, a clearly defined decrease in the S and G2 phases, i.e., almost complete cell disappearance during mitosis.

![Cell cycle phases of the Neuro 2A cells treated with compound **12c** (0.2 nM) and incubated with test compounds for 48 h (A) and (B) 72 h, respectively.](ao9b03826_0002){#fig4}

The obtained data suggest that under the action of lembehyne B, the mouse neuroblastoma cells are likely to undergo differentiation, which is confirmed by the activation of neuritogenesis.

3. Conclusions {#sec3}
==============

Thus, as a continuation of our research on the development of original methods for the stereoselective synthesis of natural alkynols containing bis-methylene-separated Z-double bonds, we synthesized a series of 1,3-diyne analogues of natural lembehyne in high yields and with high selectivity. Biological activity assays in vitro revealed the high potential of these compounds as bases for the development of modern antitumor or neuritogenic agents for the treatment of socially significant human diseases. Currently, we are carrying out intensive research in this area dealing with the investigation of the molecular mechanisms of lembehyne-induced neuritogenesis and the antitumor activity of natural and synthetic lembehynes using advanced molecular biological approaches of flow cytometry, multiparameter analysis of signaling pathways, immunohistochemical studies, Western blotting, and fluorescence spectroscopy.

4. Experimental Section {#sec4}
=======================

4.1. Materials and Methods {#sec4.1}
--------------------------

All solvents were dried (1,4-dioxane, tetrahydrofuran, diethyl ether over Na) and freshly distilled before use. All reactions were carried out under a dry argon atmosphere. ^1^H and ^13^C NMR spectra were obtained using a Bruker AVANCE 400 spectrometer in CDCl~3~ operating at 400 MHz for ^1^H and 100 MHz for ^13^C. High-resolution mass spectra (HRMS) were measured on an instrument using a time-of-flight (TOF) mass analyzer with electrospray ionization (ESI). Elemental analyses were performed on an 1106 Carlo Erba apparatus. The individuality and purity of the synthesized compounds were controlled using thin-layer chromatography (TLC) on Sorbfil plates; anisic aldehyde in acetic acid was used as a developer. Column chromatography was carried out on an Acrus silica gel (0.060--0.200 mm). Aliphatic and oxygenated 1,2-dienes and lembehyne B have been synthesized according to previously developed procedures.^[@ref21]−[@ref24]^

4.2. Synthesis {#sec4.2}
--------------

### 4.2.1. Cross-Cyclomagnesiation of Nonadeca-1,2-diene (**1**) and 2-Tetradeca-12,13-dien-1-yl-1,3-dioxolane (**6**) with EtMgBr in the Presence of Mg Metal and a Cp~2~TiCl~2~ Catalyst {#sec4.2.1}

Diethyl ether (30 mL), nonadeca-1,2-diene (**1**) (1.27 g, 4.8 mmol), 2-tetradeca-12,13-dien-1-yl-1,3-dioxolane (**2**) (1.06 g, 4.0 mmol), EtMgBr (12.0 mmol) (as 1.5 M solution in Et~2~O), Mg powder (0.19 g, 8.0 mmol), and Cp~2~TiCl~2~ (0.1 g, 0.4 mmol) were placed in a glass reactor with stirring under argon (∼0 °C). The reaction mixture was warmed up to room temperature (20--22 °C) and stirred for 6 h. The reaction mixture was quenched with a 10% solution of HCl in H~2~O (20 mL) and extracted with diethyl ether (2 × 100 mL). The combined organic phases were then dried over MgSO~4~, filtered, and the solvents were removed under vacuum. Silica gel column chromatography (hexane/EtOAc, 35:1) of the residue gave dienal **4** (1.50 g, 77%) as a pale yellow oily liquid.

#### 4.2.1.1. (13*Z*,17*Z*)-Tetraconta-13,17-dien-1-al (**4**) {#sec4.2.1.1}

^1^H NMR (400 MHz) δ  0.88 (3H, t, *J* = 6.6 Hz, C[H]{.ul}~3~), 1.42--1.15 (44H, m, C[H]{.ul}~2~), 1.56--1.66 (2H, m, C[H]{.ul}~2~), 1.96--2.10 (8H, m, C[H]{.ul}~2~--CH=), 2.40 (2H, t, *J* = 7.3 Hz,), 5.41--5.32 (4H, m, *J* = 5.4 Hz,), 9.74 (1H, s, O=CH). ^13^C NMR (100.62 MHz, CDCl~3~) δ 14.10, 22.08, 22.71, 27.21, 27.25, 27.42, 29.19, 29.34, 29.41, 29.47, 29.52, 29.58, 29.62, 29.65, 29.71, 29.75, 31.96, 43.89, 129.08, 130.25, 202.24. HRMS (ESI-TOF): calcd for C~34~H~64~O \[M + H\]^+^ 489.8793, found 489.8790. Anal. calcd for C~34~H~64~O: C, 83.53; H, 13.20. Found: C, 83.39; H, 13.16.

### 4.2.2. Procedure for the Preparation of 1,3-Diyne (**5**) {#sec4.2.2}

To a solution of 4-trimethylsilyl-1,3-butadiyne 0.73 g (6 mmol) in THF (10 mL), a solution of 4 mL *n*-BuLi (1.5 M in hexane) was added dropwise at −40 °C. The solution was stirred for 1 h at −40 to 0 °C and then added dropwise to THF solution of 1.5 g (3.08 mmol) dienal (**4**) at −10 °C. The reaction mixture was warmed up to ambient temperature and stirred for 3 days. The reaction mixture was treated with a 5% solution of NH~4~Cl in H~2~O (20 mL) and extracted with diethyl ether (2 × 100 mL). The combined organic phases were dried over MgSO~4~, filtered, and the solvents were removed under vacuum. Silica gel column chromatography of the residue gave compound **5** (1.59 g, 85%) as a pale yellow oily liquid.

#### 4.2.2.1. (17*Z*,21*Z*)-1-(Trimethylsilyl)octatriaconta-17,21-dien-1,3-diyn-5-ol (**5**) {#sec4.2.2.1}

^1^H NMR (400 MHz) δ 0.22 (9H, s, C[H]{.ul}~3~), 0.91 (3H, t, *J* = 6.6 Hz, C[H]{.ul}~3~), 1.29--1.48 (46H, m, C[H]{.ul}~2~), 1.67--1.90 (2H, m, C[H]{.ul}~2~), 2.02--2.21 (8H, m, C[H]{.ul}~2~--CH=), 4.43 (1H, t, *J* = 6.6, HO--C[H]{.ul}), 5.47--5.30 (4H, m, =CH). ^13^C NMR (100.62 MHz, CDCl~3~) δ −0.47, 14.14, 22.71, 25.03, 27.28, 27.44, 29.24, 29.35, 29.39, 29.51, 29.59, 29.65, 29.68, 29.72, 29.77, 31.95, 37.49, 62.86, 69.78, 78.73, 87.22, 87.58, 129.16, 130.38. HRMS (ESI-TOF): calcd for C~41~H~74~OSi \[M + H\]^+^ 612.1191, found 612.1193. Anal. calcd for C~41~H~74~OSi: C, 80.58; H, 12.20. Found: C, 80.55; H, 12.22.

### 4.2.3. Procedure for the Preparation of 1,3-Diynoles (**6**) {#sec4.2.3}

To a solution of alkyne (**5**) 1.17 g (2 mmol) in THF (10 mL), TBAF (1 M in THF, 1.2 equiv) was added at 0 °C, the solution was stirred for 4 h at ambient temperature and then added dropwise to a THF solution of 1.5 g (3.08 mmol) dienal (**6**) at −10 °C. The reaction mixture was treated with saturated aq. NaCl and extracted with diethyl ether (2 × 50 mL). The combined organic phases were dried over MgSO~4~, filtered, and the solvents were removed under vacuum. Silica gel column chromatography of the residue gave compound **6** (1.07 g, 99%) as a colorless waxy solid.

#### 4.2.3.1. (17*Z*,21*Z*)-Octatriaconta-17,21-dien-1,3-diyn-5-ol (**6**) {#sec4.2.3.1}

^1^H NMR (400 MHz) δ 0.90 (3H, t, *J* = 6.7, C[H]{.ul}~3~), 1.54--1.19 (46H, m, C[H]{.ul}~2~), 1.67--1.77 (2H, m, C[H]{.ul}~2~), 2.03--2.10 (8H, m, C[H]{.ul}~2~--CH=), 2.21 (1H, s, C[H]{.ul}), 4.43 (1H, t, *J* = 6.6, HO--CH), 5.32--5.40 (4H, m, =C[H]{.ul}). ^13^C NMR (100.62 MHz, CDCl~3~) δ 14.14, 22.72, 25.00, 27.23, 27.29, 27.42, 27.44, 29.21, 29.35, 29.39, 29.49, 29.57, 29.59, 29.64, 29.69, 29.73, 29.77, 31.95, 37.41, 62.73, 67.44, 68.40, 69.09, 129.16, 130.40. HRMS (ESI-TOF): calcd for C~38~H~66~O \[M + H\]^+^ 539.9379, found 539.9371. Anal. calcd for C~38~H~66~O: C, 84.68; H, 12.34. Found: C, 84.62; H, 12.36.

### 4.2.4. Procedure for the Preparation of 1,3-Diyne's Analogues (**12a**--**d**) {#sec4.2.4}

To a stirred solution of *n*-BuNH~2~ (0.29 mL) and distilled H~2~O (0.58 mL), copper(I) chloride (5.8 mg, 0.06 mmol) was added at 0 °C under argon, which resulted in a deep blue solution. A few crystals of NH~2~OH·HCl were added to discharge the blue color, and a solution of enynic alcohol (lembehyne B) **10** (150 mg, 0.45 mmol) in CH~2~Cl~2~ (1.16 mL) was added via a syringe at the same temperature. Then, 3-bromoprop-2-yn-1-ol (43 mg, 0.32 mmol) was added slowly. The reaction mixture was warmed to room temperature and stirred for 30 min. A few crystals of NH~2~OH·HCl were added occasionally to prevent the solution from turning green or blue throughout the reaction. Upon completion, the reaction solution was extracted with CH~2~Cl~2~. The combined organic phases were dried over anhydrous MgSO~4~ and concentrated under reduced pressure. The residue was purified by silica gel chromatography (*n*-hexane/ethyl acetate, 5:1) as a colorless oil.

#### 4.2.4.1. (18*Z*,22*Z*)-Nonatriaconta-18,22-dien-2,4-diyne-1,6-diol (**12a**) {#sec4.2.4.1}

Yield 99%. ^1^H NMR (400 MHz, CDCl~3~) δ 0.90 (3H, t, *J* = 6.7, C[H]{.ul}~3~), 1.27--1.47 (46H, m, C[H]{.ul}~2~), 1.79--1.70 (2H, m, C[H]{.ul}~2~), 2.18--1.98 (8H, m, C[H]{.ul}~2~--CH=), 4.36 (2H, s, HO--C[H]{.ul}~2~), 4.45 (1H, t, *J* = 6.6, HO--C[H]{.ul}), 5.44--5.38 (4H, m, =C[H]{.ul}). ^13^C NMR (100.62 MHz, CDCl~3~) δ 14.13, 22.71, 25.06, 27.28, 27.43, 29.24, 29.35, 29.38, 29.52, 29.59, 29.68, 29.72, 31.94, 37.48, 51.38, 62.83, 68.84, 69.81, 77.53, 80.54, 129.16, 130.38, 130.40. HRMS (ESI-TOF): calcd for C~39~H~68~O~2~ \[M + H\]^+^ 569.9639, found 569.9631. Anal. calcd for C~39~H~68~O~2~: C, 82.32; H, 12.05. Found: C, 82.36; H, 12.08.

#### 4.2.4.2. (19*Z*,23*Z*)-Tetraconta-19,23-dien-3,5-diyne-1,7-diol (**12b**) {#sec4.2.4.2}

Yield 98%. ^1^H NMR (400 MHz) δ 0.90 (3H, t, *J* = 6.7, C[H]{.ul}~3~), 1.17--1.51 (46H, m, C[H]{.ul}~2~), 1.64--1.78 (2H, m, C[H]{.ul}~2~), 1.95--2.13 (8H, m, C[H]{.ul}~2~--CH=), 2.58 (2H, t, *J* = 6.4 Hz, C[H]{.ul}~2~), 3.77 (2H, t, *J* = 6.4 Hz, HO--C[H]{.ul}~2~), 4.40 (t, *J* = 6.6, 1H, HO--C[H]{.ul}), 5.37--5.43 (m, 4H, =C[H]{.ul}). ^13^C NMR (100.62 MHz, CDCl~3~) δ 14.13, 22.71, 23.62, 25.13, 27.28, 27.43, 29.29, 29.35, 29.39, 29.57, 29.62, 29.68, 29.72, 29.78, 31.95, 37.58, 60.63, 62.73, 66.15, 69.45, 77.38, 78.00, 129.15, 130.36. HRMS (ESI-TOF): calcd for C~40~H~70~O~2~ \[M + H\]^+^ 583.9905, found 583.9900. Anal. calcd for C~40~H~70~O~2~: C, 82.40; H, 12.10. Found: C, 82.39; H, 12.15.

#### 4.2.4.3. (20*Z*,24*Z*)-Hentetraconta-20,24-dien-4,6-diyne-1,8-diol (**12c**) {#sec4.2.4.3}

Yield 97%. ^1^H NMR (400 MHz) δ 0.90 (3H, t, *J* = 6.7, C[H]{.ul}~3~), 1.28--1.47 (48H, m, C[H]{.ul}~2~), 1.66--1.85 (2H, m, C[H]{.ul}~2~), 1.95--2.10 (8H, m, C[H]{.ul}~2~--CH=), 2.44 (2H, t, *J* = 6.4 Hz, C[H]{.ul}~2~), 3.77 (2H, t, *J* = 6.4 Hz, HO--C[H]{.ul}~2~), 4.41 (1H, t, *J* = 6.6, HO--C[H]{.ul}), 5.38--5.45 (4H, m, =C[H]{.ul}). ^13^C NMR (100.62 MHz, CDCl~3~) δ 14.14, 15.83, 22.71, 25.09, 27.28, 27.43, 29.27, 29.35, 29.39, 29.54, 29.60, 29.68, 29.72, 30.80, 31.95, 37.65, 61.30, 62.85, 64.92, 69.68, 76.87, 80.65, 129.16, 130.38. HRMS (ESI-TOF): calcd for C~41~H~72~O~2~ \[M + H\]^+^ 598.0171, found 598.0177. Anal. calcd for C~41~H~72~O~2~: C, 82.48; H, 12.16. Found: C, 82.24; H, 12.09.

#### 4.2.4.4. (21*Z*,25*Z*)-Dotetraconta-21,25-dien-5,7-diyne-1,9-diol (**12d**) {#sec4.2.4.4}

Yield 98%. ^1^H NMR (400 MHz) δ 0.90 (3H,t, *J* = 6.7, C[H]{.ul}~3~), 1.19--1.49 (50H, m, C[H]{.ul}~2~), 1.61--1.78 (2H, m, C[H]{.ul}), 2.10--1.96 (8H, m, C[H]{.ul}~2~--CH=), 2.36 (2H,t, *J* = 6.4 Hz, C[H]{.ul}~2~), 3.69 (2H,t, *J* = 6.4 Hz, HO--C[H]{.ul}~2~), 4.40 (1H, t, *J* = 6.6, HO--C[H]{.ul}), 5.31--5.44 (4H, m, =C[H]{.ul}). ^13^C NMR (100.62 MHz, CDCl~3~) δ 14.13, 19.09, 22.70, 24.50, 25.10, 27.28, 27.43, 29.27, 29.35, 29.38, 29.54, 29.59, 29.67, 29.72, 29.77, 31.68, 31.94, 37.66, 62.22, 62.81, 64.85, 69.71, 76.86, 81.08, 129.15, 130.37. HRMS (ESI-TOF): calcd for C~42~H~74~O~2~ \[M + H\]^+^ 612.0437, found 612.0433. Anal. calcd for C~42~H~74~O~2~: C, 82.55; H, 12.20. Found: C, 82.51; H, 12.22.

4.3. Biological Assays {#sec4.3}
----------------------

### 4.3.1. Cell Culture {#sec4.3.1}

Human cancer cell lines HeLa and Hek293 were obtained from the HPA Culture Collections (U.K.). Cells (U937, K562, Jurkat) were purchased from the Russian Cell Culture Collection (Institute of Cytology of the Russian Academy of Sciences) and cultured according to standard protocols and a sterile technique. The cell lines were shown to be free from viral contamination and mycoplasma. HeLa and Hek293 cell lines were cultured as monolayers and maintained in Dulbecco's modified Eagle's medium (DMEM, Gibco BRL) supplemented with 10% fetal bovine serum (FBS) and a 1% penicillin--streptomycin solution at 37 °C in a humidified incubator under a 5% CO~2~ atmosphere. Cells were maintained in RPMI 1640 (Jurkat, K562, U937) (Gibco) supplemented with 4 μM glutamine, 10% FBS (Sigma), and 100 units/mL penicillin--streptomycin (Sigma). All types of cells were grown in an atmosphere of 5% CO~2~ at 37 °C. The cells were subcultured at 2--3 days intervals. Adherent cells (HeLa) were suspended using trypsin/ethylenediaminetetraacetic acid (EDTA) and counted after they had reached 80% confluency. Cells were then seeded in 24-well plates at 5 × 10^4^ cells per well and incubated overnight. Jurkat, K562, and U937 cells were subcultured at 2-day intervals with a seeding density of 1 × 10^5^ cells per 24-well plate in RPMI with 10% FBS. Mouse neuroblastoma Neuro 2A cells were obtained from the American Type Culture Collection (ATCC). Cells were grown in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS, Hyclone) at 37 °C in a humidified atmosphere with 5% CO~2~.

### 4.3.2. Cytotoxicity Assay {#sec4.3.2}

A viability (Live/Dead) assessment was performed by staining cells with 7-aminoactinomycin D (7-AAD) (Biolegend). After treatment, cells were harvested, washed 1--2 times with phosphate-buffered saline (PBS), and centrifuged at 400*g* for 5 min. Cell pellets were resuspended in 200 μL of flow cytometry staining buffer (PBS without Ca^2+^ and Mg^2+^, 2.5% FBS) and stained with 5 μL of a 7-AAD staining solution for 15 min at room temperature in the dark. Samples were acquired on a NovoCyte TM 2000 Flow Cytometry System (ACEA) equipped with a 488 nm argon laser. Detection of 7-AAD emission was performed through a 675/30 nm filter in the FL4 channel.

### 4.3.3. Viability and Apoptosis {#sec4.3.3}

Apoptosis was studied using flow cytometric analysis of annexin V and 7-aminoactinomycin D staining. After treatment, cells were harvested for 24 h, washed 1--2 times with phosphate-buffered saline (PBS), and centrifuged at 400*g* for 5 min. Cell pellets were resuspended in 200 μL of flow cytometry staining buffer (PBS without Ca^2+^ and Mg^2+^, 2.5% FBS). Then, 200 μL of Guava Nexin reagent (Millipore, Bedford, MA) was added to 5 × 10^5^ cells in 200 μL, and the cells were incubated with the reagent for 20 min at room temperature in the dark. At the end of incubation, the cells were analyzed on a NovoCyte TM 2000 Flow Cytometry System (ACEA).

### 4.3.4. Cell Cycle Analysis {#sec4.3.4}

The cell cycle was analyzed using the method of propidium iodide staining. After treatment, cells were harvested for 24 h, washed 1--2 times with phosphate-buffered saline (PBS), and centrifuged at 400*g* for 5 min. Cell pellets were resuspended in 200 μL of flow cytometry staining buffer (PBS without Ca^2+^ and Mg^2+^, 2.5% FBS). Then, cells were plated in 24-well round-bottom plates at a density of 10 × 10^5^ cells per well, centrifuged at 450*g* for 5 min, and fixed with ice-cold 70% ethanol for 24 h at 0 °C. Cells were then washed with PBS and incubated for 30 min at room temperature with 250 μL of Guava Cell Cycle Reagent (Millipore) in the dark. Samples were analyzed on a NovoCyte TM 2000 Flow Cytometry System (ACEA).

### 4.3.5. Cell Differentiation Assay {#sec4.3.5}

The Neuro 2A cells were plated on 24-well plates at a density of 1 × 10^4^ cells/cm^2^ with 1 mL of the culture medium. After a 24 h cultivation, the medium was exchanged for a fresh medium, and a testing sample of 10 mL of an ethanol solution was added to each well. After 12, 24, 48, and 72 h incubations, morphological changes in the cells were observed under a phase-contrast microscope. The cells that had processes longer than the diameter of the cell body were evaluated as neurite-bearing cells. The percentage of the cells with neurites in a particular culture was determined by counting at least 300 cells in the photomicrographs of the areas where the cell density was representative.
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